ClinicalTrials.gg
RecruitingNCT02421705Updated Oct 22, 2026

Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)

An interventional study of Sample collection in IBS, Ulcerative Colitis, Active and Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms), sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by KU Leuven · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Mar 2010, registered Jul 2013).
  • Started Mar 2010; still recruiting 16 years 8 months later.
Updated Oct 22, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
99,999,999
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies in Colitis, Ulcerative with a site in Belgium — 26 open to participants now, 50 under way, 27 of them phase 3. Colitis, Ulcerative · Belgium.

Planned enrollment
Largest of 168
99,999,999 · median 198
Started
2010
with 2 others
No phase
5 of 187
3 open now
Primary completion
2099-01
later than 49 of 49 live
Registered
56th of 187
by date

Among the 187 studies in Colitis, Ulcerative with a site in Belgium, this one has the largest planned enrollment of the 168 interventional ones that give a count, is one of 3 that started in 2010, is one of 5 with no phase, reaches primary completion later than 49 of the 49 other live ones, and was the 56th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

26 of the 187 studies in Colitis, Ulcerative with a site in Belgium are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Colitis, Ulcerative with a site in Belgium, or all of them as a file.
02

Study summary

Aim:

More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

Read the detailed description

Methods:

Sample collection in healthy subjects, IBD and IBS patients:

  • biopsy of rectum and colon descendens
  • blood sample collection
  • collection of sample of nasal mucosa
  • feces collection
  • questionnaires
  • rectal barostat sensitivity measurement
  • transit measurement of colon
  • MR scan of brain
03

Conditions studied

  • IBS
  • Ulcerative Colitis, Active
  • Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms)
  • Healthy Controls
  • Crohn's Disease, Active
  • Crohn's Disease, Remission (6a: With IBS Symptoms, 6b: Without IBS Symptoms)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For group 1: IBS

  1. Irritable Bowel Syndrome (IBS) (ROME III criteria)
  2. No obvious organic explanation for the IBS symptoms
  3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study

Group 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study

Group 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms)

  1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy)
  2. remission is confirmed by at least one sigmoidoscopy
  3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study

    Only for group 3a:

  4. Rome III criteria for IBS

Group 4: Healthy controls No abdominal (pain) complaints.

Group 5: active Crohn's disease

1. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study

Group 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms)

  1. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy)
  2. remission is confirmed by at least one sigmoidoscopy
  3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study

Exclusion criteria

Exclusion Criteria:

For all groups:

  1. co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting
  2. Abdominal chirurgy (except for an uncomplicated appendectomy)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
99,999,999 participants (estimated)

Study arms

  • Other
    Sample collection

    Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon

    Other: Sample collection

Interventions

  • OtherSample collection

    Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon

06

What researchers measure

Primary outcomes

  1. differences in visceral sensitivity in different study groups (Visceral sensitivity will me measured by performing a rectal barostat test)

    Visceral sensitivity will me measured by performing a rectal barostat test

    Time frame: at time of investigation (rectal barostat test), Day 1

Secondary outcomes

  1. immune activity (measuring release of mest cell mediators in rectal biopsies, measuring parameters of immune activity in blood)

    measuring release of mest cell mediators in rectal biopsies, measuring parameters of immune activity in blood (for example by stimulating Peripheral Blood Mononuclear Cells)

    Time frame: at time of investigation (rectal biopsy), Day 1

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2010 (actual). Primary completion is estimated for Jan 2099, 1,066 months after the start.

Of 228 non-industry interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 1,066 months is above that.

Counting every sponsor, half of 239 studies reached it within 34 months; a quarter within 15 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Feb 2010 → Mar 2010, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2013
First posted
Apr 21, 2015
StartActual
Mar 12, 2010was Feb 2010
Primary completionEst.
Jan 2099
CompletionEst.
Jan 2099
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 2010→Mar 12, 2010 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Feb 2010→Mar 12, 2010 (now actual)
    + 3 other changes: index terms, verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02421705
Lead sponsor
KU Leuven
Responsible party
Guy Boeckxstaens (Prof. Dr., KU Leuven) — Principal investigator
First posted
Apr 21, 2015
Start date
Mar 12, 2010
Primary completion
Jan 2099 (estimated)
Completion
Jan 2099 (estimated)
Last update
Oct 22, 2026

Study contacts

Koen Bellens, MSc
Contact
koen.bellens@kuleuven.be
0032-16-341943
Guy Boeckxstaens, MD
principal investigator · Catholic University Leuven and Universitary Hospitals Leuven

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion